Michael J. Reardon, MD, professor of cardiothoracic surgery and Allison Family Distinguished chair of cardiovascular research at Houston Methodist DeBakey Heart and Vascular Center, presented pooled data at ACC.22 from the CoreValve SURTAVI trials that found transcatheter aortic valve replacement (TAVR) was more durable than surgical aortic valve replacement (SAVR) devices.

The new algorithm was designed to evaluate a user's heart rhythm while they are still or even sleeping. 

Adam Greenbaum, MD, co-director of the Structural Heart and Valve Center at Emory University Hospital Midtown in Atlanta, explains details from the late-breaking CLASP TR trial at ACC.22.

Several late-breaking clinical trials at ACC.22 will likely impact clinical practice. Below are summaries of a few key trials and their takeaways for interventional cardiology and structural heart interventions. 

Sean Pokorney, MD, director of the arrhythmia core lab, Duke Clinical Research Institute, assistant professor of Medicine, Duke University, discusses a late-breaking ACC 2022 study that shows mortality is higher in patients with implantable electrophysiology (EP) device infections where the leads are not explanted.

A Chinese study of 2.8 million participants found that 94% of users flagged for AFib indeed have the heart rhythm disorder.

The study's authors examined data from the DANAMI-3 trial, focusing on such outcomes as all-cause mortality, recurrent MI and target vessel revascularization.

Santiago Garcia, MD, lead author of the study and director of the structural heart program at The Christ Hospital in Cincinnati, Ohio, presented new data from the North American COVID-19 STEMI (NACMI) registry at ACC.22. Severity of heart attacks were reduced in vaccinated patients, with zero deaths in vaccinated patients in 2021.